Mylan gets nod to market UCB’s epilepsy drug

Mylan Inc., the biggest US maker of generic drugs, has informed that it has received approval to market a generic version of Levetiracetam Tablets.

The company said that Food and Drug Administration has approved its application to market generic versions of the drug, also called Levetiracetam, in 250 milligram, 500 mg and 750 mg tablets.

Levetiracetam Tablets are the generic version of UCB Pharma's Keppra, which is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

The latest reports revealed that, the U.S.sales of Keppra totaled about $1 billion in the 12 months ended Sept. 30.

Mylan shares were presently trading at $ 610, up 6 per cent compared to previous close of $575.